Multivalent Small-Molecule Pan-RAS Inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Cell"
DOI: 10.1016/j.cell.2017.02.006
Abstract: Design of small molecules that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may provide chemical probes and therapeutic agents. We describe here the synthesis and testing of potential small-molecule pan-RAS ligands,… read more here.
Keywords: ras proteins; pan ras; small molecule; molecule pan ... See more keywords
Abstract A067: Pan-RAS inhibition as a novel therapeutic strategy in RAS-driven rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a067
Abstract: Attempts to indirectly inhibit RAS and RAS-effector signaling have been unsuccessful in RAS-driven rhabdomyosarcoma (RMS). RMC-6236 (and the related tool compound RMC-7977) are novel state-selective pan-RAS inhibitors that inhibit both GTP-bound oncogenic and wild-type (WT)… read more here.
Keywords: inhibition; driven rhabdomyosarcoma; novel; pan ras ... See more keywords
Abstract LB322: Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb322
Abstract: Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer death in the U.S. with only about a 10% five-year survival rate and an estimated 60,000 deaths/year by 2030. Poor survival is frequently due… read more here.
Keywords: adt; class pan; adt 1004; pan ras ... See more keywords
Abstract 4377: AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4377
Abstract: RAS mutations drive approximately 30% of human cancers, representing a critical unmet clinical need. AN9025, an oral RAS (ON) inhibitor, with best-in-class potential, demonstrates picomolar potency against RAS-dependent tumor cell lines, showing greater potency than… read more here.
Keywords: an9025; tumor; cell; pan ras ... See more keywords
Abstract 4389: HJ-093, a novel, orally bioavailable, and potent pan-RAS inhibitor, for the treatment of various RAS mutation-driven cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4389
Abstract: RAS mutations dominate tumorigenesis as they account for approximately 30% of human cancer cases, and are common in various solid tumor types such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal… read more here.
Keywords: cancer; ras mutation; various ras; potent pan ... See more keywords
Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207683
Abstract: Mutations in genes that code for RAS isozymes (N- and K-) are the most common (40-50%) somatic variations in multiple myeloma (MM). While ~46% of patients with newly diagnosed MM carry a RAS/Raf mutation, >64%… read more here.
Keywords: adt 007; analysis; cell; pan ras ... See more keywords